Advertisement

Analysis of clinical data associated with Essure® sterilization devices: An expanded case series

  • Cristina Sánchez-Cuerda
    Correspondence
    Corresponding author at: Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain.
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain

    European University Madrid, Tajo St, 28670 Villaviciosa de Odón, Madrid, Spain
    Search for articles by this author
  • María Cuadra
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain
    Search for articles by this author
  • Yasmina Cabrera
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain

    European University Madrid, Tajo St, 28670 Villaviciosa de Odón, Madrid, Spain
    Search for articles by this author
  • Silvia Duch
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain

    European University Madrid, Tajo St, 28670 Villaviciosa de Odón, Madrid, Spain
    Search for articles by this author
  • Sofía Fabra
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain
    Search for articles by this author
  • John Peay-Pinacho
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain
    Search for articles by this author
  • Pilar Álvarez
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain

    European University Madrid, Tajo St, 28670 Villaviciosa de Odón, Madrid, Spain
    Search for articles by this author
  • José Rubio
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain

    European University Madrid, Tajo St, 28670 Villaviciosa de Odón, Madrid, Spain
    Search for articles by this author
  • Julio Álvarez Bernardi
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain

    European University Madrid, Tajo St, 28670 Villaviciosa de Odón, Madrid, Spain
    Search for articles by this author
  • Paloma Lobo
    Affiliations
    Department of Obstetrics and Gynecology, Infanta Sofía University Hospital, Paseo de Europa 34, 28703 San Sebastián de los Reyes, Madrid, Spain

    European University Madrid, Tajo St, 28670 Villaviciosa de Odón, Madrid, Spain
    Search for articles by this author
Published:September 21, 2022DOI:https://doi.org/10.1016/j.ejogrb.2022.09.018

      Abstract

      Objectives

      To evaluate clinical data in women who underwent Essure® hysteroscopic sterilization and to determine whether this sterilization technique plays a role in developing new-onset symptoms.

      Study design

      An observational, retrospective, single-center study. It was conducted in a secondary level hospital. It included 804 women who had Essure® hysteroscopic sterilization from 2009 to 2017. Charts from these women were reviewed from June 2009 to November 2019, searching for the development of gynecological symptoms (pelvic pain and bleeding disorders) and non-gynecological symptoms (bloating, joint pain, fatigue, headache, alopecia, allergy and depression). The sample was divided into two groups depending on whether they had developed gynecological symptoms (symptomatic group) or not (asymptomatic group), and a descriptive and comparative analysis was made between them. The impact of the global social alarm in 2015 regarding adverse events attributed to the devices, the development of non-gynecological symptoms, and the treatments required, including conservative and surgical options, were also described.

      Results

      Out of 804 women who had Essure® devices placed, 541(67.29%) remained asymptomatic, 263(32.71%) developed gynecological symptoms, and 41 of these (15.5% of the total sample) requested Essure® surgical removal. Pelvic pain was the most frequent symptom and the main reason for surgical removal. Bleeding alterations were the second most frequent symptom. Up to 55.89% described the symptoms after the social alarm. Non-gynecological symptoms were statistically significantly more frequent in the symptomatic group.

      Conclusions

      More than a half of the women who underwent Essure® sterilization remained asymptomatic. The new-onset symptoms attributed to the devices are the minority and causality is difficult to establish.

      Implications Statement

      Our research provides new follow-up data about Essure® hysteroscopic sterilization. Association between gynecological symptoms and Essure® devices is difficult to demonstrate and some confounding factors may be implicated. The results we described, may guide and counsel medical-patient decisions for the treatment of symptoms related to the devices, including surgical removal.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Casey J.
        • Cedo-Cintron L.
        • Pearce J.
        • Yunker A.
        Current techniques and outcomes in hysteroscopic sterilization: current evidence, considerations, and complications with hysteroscopic sterilization micro inserts.
        Curr Opin Obstet Gynecol. 2017; 29: 218-224https://doi.org/10.1097/GCO.0000000000000369
        • Walter J.R.
        • Ghobadi C.W.
        • Hayman E.
        • Xu S.
        Hysteroscopic sterilization with essure: summary of the U.S. food and drug administration actions and policy implications for postmarketing surveillance.
        Obstet Gynecol. 2017; 129: 10-19https://doi.org/10.1097/AOG.0000000000001796
      1. Clark NV, Endicott SP, Jorgensen EM, Hur HC, Lockrow EG, Kern ME, Jones-Cox CE, Dunlow SG, Einarsson JI, Cohen SL. Review of Sterilization Techniques and Clinical Updates. J Minim Invasive Gynecol. 2018 Nov-Dec;25(7):1157-1164. doi: 10.1016/j.jmig.2017.09.012. Epub 2017 Sep 20.

        • Bouillon K.
        • Bertrand M.
        • Bader G.
        • Lucot J.
        • Dray-Spira R.
        • Zureik M.
        Association of hysteroscopic vs laparoscopic sterilization with procedural, gynecological, and medical outcomes.
        Obstet Gynecol Surv. 2018; 73: 285-286
        • Al-Safi Z.
        • Shavell V.
        • Hobson D.
        • Berman J.
        • Diamond M.
        Analysis of adverse events with essure hysteroscopic sterilization reported to the manufacturer and user facility device experience database.
        J Minim Invasive Gynecol. 2013; 20: 825-829
        • Maassen L.
        • van Gastel D.
        • Haveman I.
        • Bongers M.
        • Veersema S.
        Removal of essure sterilization devices: a retrospective cohort study in the Netherlands.
        J Minim Invasive Gynecol. 2019; 26: 1056-1062
      2. E.V.J. Van Limburg Stirum N.V. Clark A. Lindsey X. Gu A.L. Thurkow J.I. Einarsson et al. Factors Associated with Negative Patient Experiences with Essure Sterilization JSLS. Jan-Mar;24(1) 2020 e2019.00065 10.4293/JSLS.2019.00065.

        • Clark N.
        • Rademaker D.
        • Mushinski A.
        • Ajao M.
        • Cohen S.
        • Einarsson J.
        Essure removal for the treatment of device-attributed symptoms: an expanded case series and follow-up survey.
        J Minim Invasive Gynecol. 2017; 24: 971-976
      3. FDA Meeting of the Obstetrics and Gynecology Devices Advisory Panel September 24, 2015. Maude Database. Fdanews.com. Available from: https://www.fdanews.com/ext/resources/files/2016/09/09-07-16-Essure.pdf?1517068918.

      4. Guía de actuación ante una paciente portadora del dispositivo Essure® (2018). Sociedad Española de Ginecología y Obstetricia [Internet]. Sego.es. Available from: https://sego.es.

      5. Jegaden M, Pourcelot AG, Fernandez H, Capmas P. Surgical removal of essure® micro inserts by vaginal hysterectomy or laparoscopic salpingectomy with cornuectomy: Case series and follow up survey about device-attributed symptoms resolution. J Gynecol Obstet Hum Reprod. 2020 Oct;49(8):101781. doi: 10.1016/j.jogoh.2020.101781. Epub 2020 May 31.

        • Siemons S.E.
        • Vleugels M.P.H.
        • Veersema S.
        • Braat D.D.M.
        • Nieboer T.E.
        Long-term follow-up after successful Essure sterilization: evaluation of patient satisfaction, symptoms, and the influence of negative publicity.
        Fertil Steril. 2019; 112: 1144-1149https://doi.org/10.1016/j.fertnstert.2019.08.008
        • Casey J.
        • Aguirre F.
        • Yunker A.
        Outcomes of laparoscopic removal of the Essure sterilization device for pelvic pain: a case series.
        Contraception. 2016; 94: 190-192
        • Chene G.
        • Cerruto E.
        • Moret S.
        • Lebail-Carval K.
        • Chabert P.
        • Mellier G.
        • et al.
        Quality of life after laparoscopic removal of Essure® sterilization devices.
        Eur J Obstet Gynecol Reproduct Biol X. 2019; 3100054
        • Kamencic H.
        • Thiel L.
        • Karreman E.
        • Thiel J.
        Does essure cause significant de novo pain? a retrospective review of indications for second surgeries after essure placement.
        J Minim Invasive Gynecol. 2016; 23: 1158-1162
        • Leleu A.
        • Cathelain A.
        • Rubod C.
        • Vandendriessche D.
        • Cosson M.
        • Giraudet G.
        Symptom related to Essure® and evolution after removal: Outcomes of retrospective cohort.
        J Gynecol Obstet Hum Reprod. 2021; 50 (Epub 2020 Jun 24)101836https://doi.org/10.1016/j.jogoh.2020.101836
      6. Franchini M, et al. Essure Permanent Birth Control, Effectiveness and Safety: An Italian 11-Year Survey. J Minim Invasive Gynecol. 2017 May-Jun;24(4):640-645. doi: 10.1016/j.jmig.2017.02.004. Epub 2017 Feb 14.

      7. Menoguía. Perimenopausia, Sociedad Española de Ginecología y Obstetricia [Internet] Sego.es. Available from 2012 https://sego.es.

        • Vico Zuñiga I.
        • Rodrñiguez Oliver A.J.
        • Fernández Parra J.
        • González Paredes A.
        • Aguilar Romero M.T.
        Dolor pélvico asociado a la colocación del dispositivo Essure y alergia al níquel.
        A propósito de 3 casos. Clínica e investigación en Ginecología y Obstetricia. 2013